The KEYNOTE-799 study is evaluating pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, explained the design of the ongoing KEYNOTE-799 study (NCT03631784) which is evaluating pembrolizumab (Keytruda) plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
Transcription:
KEYNOTE-799 is a phase 2, open-label, non-randomized study which evaluated pembrolizumab with concurrent chemoradiation therapy for stage III unresectable non–small cell lung cancer.
In cohort A, patients received carboplatin, paclitaxel, and pembrolizumab for 1 cycle; followed by concurrent chemoradiation therapy…
